

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Inmazeb. [Updated 2023 Sep 15]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Inmazeb

Revised: September 15, 2023.

CASRN: 2135632-29-8; 2135632-36-7; 2135632-30-1

Drug Levels and Effects

Summary of Use during Lactation

Inmazeb is a mixture of monoclonal antibodies, atoltivimab, maftivimab, and odesivimab that are directed against *Zaire ebolavirus* glycoprotein. No information is available on the use of Inmazeb during breastfeeding. Because Inmazeb is a mixture of large protein molecules with molecular weights of 144,000 to 146,000 Da, the amount in milk is likely to be very low and absorption is unlikely because the antibodies are probably destroyed in the infant's gastrointestinal tract. Until more data become available, Inmazeb should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The US Centers for Disease Control and Prevention recommend that patients with confirmed *Zaire ebolavirus* not breastfeed their infants to reduce the risk of postnatal transmission of *Zaire ebolavirus* infection.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Inmazeb

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

CAS Registry Number

2135632-29-8; 2135632-36-7; 2135632-30-1

Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Monoclonal

Antibodies, Viral

Antiviral Agents